
Opinion|Videos|October 28, 2024
Exploring Emerging Data in NMIBC
Key Takeaways
- BladderGATE trial explores frontline use of PD1+BCG, showing promise in bladder cancer treatment advancements.
- Enfortamab vedotin and pembrolizumab combination is under investigation, potentially enhancing therapeutic efficacy.
Panelists discuss existing and upcoming data in non–muscle-invasive (NMIBC) bladder cancer treatment, including insights from the BladderGATE trial on frontline use of PD-1 inhibitors combined with BCG and the enfortamab vedotin plus pembrolizumab combination while also addressing the significance of clinical complete response as an end point and the potential role of circulating tumor DNA in future evaluations.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What other data exists? What upcoming data are you excited about? * (bladdergate, First Results of the Phase Ib-II BladderGATE exploring frontline use of PD1+BCG etc.)
- Enfortamab vedotin plus pembrolizumab combination
- Please discuss clinical complete response as an end point for these trials. What about circulating tumor DNA?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
2
Study shows variability in response to long-term tamsulosin therapy
3
Managing Immune-Related Adverse Events With Durvalumab Plus BCG in NMIBC
4
Bringing POTOMAC Data Into Community Urology Practice for High-Risk NMIBC
5




